DrugBiological
Dostarlimab clinical trials
Also written TSR-042, Jemperli and ANB011.
- studies test it
- 78
- open now
- 30
- in phase 3
- 11
- first study started
- 2010
Keep track of what changes. Save the dostarlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
78 studies that test it; most in 2020 (12)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 12 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 12 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 58
- Phase 3
- 11
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 47
GlaxoSmithKline (23) · Tesaro, Inc. (6) · M.D. Anderson Cancer Center (4) · University Health Network, Toronto (3) · Grupo Español de Investigación en Cáncer de Ovario (2) · Massachusetts General Hospital (2) · ARCAGY/ GINECO GROUP (2) · University of Iowa (2)
Often tested with
Tested in the same studies.
Niraparib (27) · Belrestotug (6) · Pembrolizumab (5) · Cobolimab (5) · Paclitaxel (5) · Bevacizumab (5) · Nelistotug (4) · Carboplatin (4)
Studies
Open first, then newest update. How each study uses dostarlimab is read from its arms, and is right about nine times in ten.
Testing it · 78
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07860450Written as Dostarlimab
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingPhase 1/2GlaxoSmithKlineNCT06796907Written as Dostarlimab
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 2University Health Network, TorontoNCT07408063Written as Dostarlimab
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Written as Niraparib + TSR-042 (Dostarlimab)
- DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyRecruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT06059495Written as Dostarlimab
- Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaRecruitingPhase 2Chang Gung Memorial HospitalNCT07336147Written as Dostarlimab
- A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07740720Written as Dostarlimab
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06065462Written as Dostarlimab
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 4GlaxoSmithKlineNCT07652515Written as Dostarlimab
- Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersRecruitingPhase 2University of IowaNCT05239546Written as Dostarlimab
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT05819892Written as Dostarlimab
- A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaRecruitingPhase 3GlaxoSmithKlineNCT06256588Written as Dostarlimab
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingPhase 2GlaxoSmithKlineNCT06567782Written as Dostarlimab
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Written as Dostarlimab
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingPhase 2Yonsei UniversityNCT06023862Written as Dostarlimab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
- Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerRecruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT06830239Written as Dostarlimab
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721Written as Dostarlimab
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07381777Written as Dostarlimab
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3GlaxoSmithKlineNCT05855200Written as Dostarlimab
See all 78 studies that test dostarlimab →
Given in every arm · 18 — dostarlimab is usual care beside what is tested
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04165772Written as TSR-042 or Dostarlimab
- Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04774419Written as Dostarlimab
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingPhase 3GlaxoSmithKlineNCT07684599Written as Dostarlimab
- PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer PatientsRecruitingPhase 3Centre Hospitalier Universitaire DijonNCT06762405Written as Dostarlimab
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingPhase 2GlaxoSmithKlineNCT06062420Written as Dostarlimab
- A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid TumorsTerminatedPhase 1GlaxoSmithKlineNCT03843359Written as Dostarlimab
- Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2Grupo Español de Tratamiento de Tumores de Cabeza y CuelloNCT05784012Written as Dostarlimab
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Dostarlimab
- Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedPhase 1GlaxoSmithKlineNCT04544995Written as Dostarlimab
- A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 1/2iOncturaNCT06879717Written as Dostarlimab
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedPhase 1Tesaro, Inc.NCT03307785Written as TSR-042
- Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2TerminatedPhase 1Elevation OncologyNCT05980416Written as Dostarlimab
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingPhase 1Tesaro, Inc.NCT02817633Written as TSR-042
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3CompletedPhase 2GlaxoSmithKlineNCT06926673Written as Dostarlimab
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as Dostarlimab
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedPhase 1Tesaro, Inc.NCT03250832Written as Dostarlimab
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsCompletedPhase 2Tesaro, Inc.NCT03308942Written as TSR-042 (Dostarlimab)
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnPhase 3Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT03806049Written as TSR042
Codes
What other systems call dostarlimab · ClinicalTrials.gg INT001720
- MeSH (NLM) C000719628dostarlimabOne source ClinicalTrials.gov
- UNII (FDA) P0GVQ9A4S5DOSTARLIMABConfirmed FDA, Wikidata
- RxNorm 2539967One source FDA
- Wikidata Q85757472dostarlimabConfirmed FDA, Wikidata
- NCI Thesaurus C126799DostarlimabOne source FDA
- DrugBank DB15627One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719628 | dostarlimab | One source ClinicalTrials.gov |
| UNII (FDA) | P0GVQ9A4S5 | DOSTARLIMAB | Confirmed FDA, Wikidata |
| RxNorm | 2539967 | — | One source FDA |
| Wikidata | Q85757472 | dostarlimab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C126799 | Dostarlimab | One source FDA |
| DrugBank | DB15627 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.